Evidence map›Paper›PMID 31312098›Full record

ArticleTropical medicine and health2019

Pharmacokinetic analysis of new synthetic antimalarial N-251.

Kazuaki Okada, Akira Sato, Akiko Hiramoto, Rena Isogawa, Yuji Kurosaki, Kazutaka Higaki, Shin-Ichi Miyoshi, Kyung-Soo Chang, Hye-Sook Kim

Abstract read
In one paragraph

Article in Tropical medicine and health, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Kazuaki Okada1Division of International Infectious Diseases Control, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Akira Sato1Division of International Infectious Diseases Control, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Akiko Hiramoto1Division of International Infectious Diseases Control, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Rena Isogawa1Division of International Infectious Diseases Control, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Yuji Kurosaki3Department of Pharmaceutical Formulation Design, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Kazutaka Higaki4Department of Pharmaceutics, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Shin-Ichi Miyoshi5Department of Sanitary Microbiology, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.
Kyung-Soo Chang6Department of Clinical Laboratory Science, College of Health Sciences, Catholic University of Pusan, Busan, 46252 Republic of Korea.
Hye-Sook Kim1Division of International Infectious Diseases Control, Faculty of Pharmaceutical Sciences, Okayama University, 1-1-1 Tsushima-Naka, Kita-Ku, Okayama, Okayama 700-8530 Japan.ORCID 0000-0001-6142-5983

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundWith the emergence and growing number of drug-resistant

resultsPK study of N-251 after intravenous and oral administration in mice showed plasma concentration of N-251 was decreased drastically by intravenous route.

conclusionsN-251 has been selected as a potent antimalarial candidate. We found that N-251 showed short half-life in plasma, and AUCs increased proportionally to dose. With multiple doses of N-251, the plasma level of N-251 was greater than 10 ng/mL in normal-fed mice, and accumulation of N-251 was not observed; however, multiple treatments with N-251 are required for the complete cure of parasite-infected mice. Determining the appropriate dosage was an important step in the clinical applications of N-251.

Indexed as

6-(1,2,6,7-tetraoxaspiro [7.11] nonadec-4-yl)hexan-1-ol (N-251)Antimalarial medicineBioavailability (F)Pharmacokinetic (PK) studySynthetic endoperoxide

Identifiers

PMID31312098
PMCPMC6611044

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.